Trial · NCT02786277
Learning Alerts for Acute Kidney Injury
NCT02786277, Not applicable, Completed, Yale University; results first posted 2025-10-08
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Learning Alerts for Acute Kidney Injury. Trials, record NCT02786277. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02786277
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Learning Alerts for Acute Kidney Injury
- NCT number
- NCT02786277
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 2,046 participants, actual
- Lead sponsor
- Yale University
- Conditions
- Acute Kidney Injury
- Interventions
- Alert
- First posted
- 2016-05-30
- Last updated
- 2025-10-08
- Results first posted
- 2025-10-08
- Limitations and caveats
This trial was randomized at the patient level, introducing the possibility of bias towards the null. It was conducted within a single health system, limiting generalizability. The alert was largely informational with no patient-specific recommendations (not accounting for AKI heterogeneity).
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Patients With Progression to a Higher Stage of AKI OR Dialysis OR Death | Within 14 days from randomization | Progression of AKI is defined as the increase in KDIGO stage from the time of randomization to the present. For patients who are discharged, we will impute 14-day creatinine using the last observation carried forward method. Dialysis is defined as the receipt of hemodialysis, continuous renal replacement therapy, or peritoneal dialysis. Isolated ultrafiltration treatments will not be included. Mortality will be determined from hospital administrative records. |
| Secondary | 14-day Mortality | Assessed from point of randomization to date of death within 14 days of randomization | Proportion of patients who expire from any cause |
| Secondary | Inpatient Mortality | Assessed from point of randomization to date of death from any cause, up to one year post-randomization | Proportion of patients who expire from any cause |
| Secondary | 14-day Dialysis | Assessed from point of randomization to date of first documented dialysis order, within 14 days of randomization | Proportion of patients who receive dialysis (hemodialysis, continuous renal replacement therapy, or peritoneal dialysis) |
| Secondary | Inpatient Dialysis | Assess from point of randomization to date of first documented dialysis order during index hospitalization, up to one year post-randomization | Proportion of patients who receive dialysis (hemodialysis, continuous renal replacement therapy, or peritoneal dialysis) |
| Secondary | Discharge on Dialysis | Assessed at point of discharge from index hospitalization, up to one year post-randomization | Assessed as active orders for dialysis at point of discharge from index hospitalization |
| Secondary | Progression to Stage 2 AKI | Assessed from the date of randomization to 14 days post randomization | Progression to Stage 2 AKI is defined as a doubling of serum creatinine between randomization and 14 days post randomization, and is considered a worsening of AKI. |
| Secondary | Progression to Stage 3 AKI | Assessed from the date of randomization to 14 days post randomization | Progression to Stage 3 AKI is defined as a tripling of serum creatinine between the date of randomization and 14 days post randomization, and is considered a worsening of AKI. |
| Secondary | Duration of AKI | Assessed from the date of randomization to the cessation of AKI during index hospitalization, up to one year | Defined as the time in hours between AKI onset and AKI cessation during index hospitalization |
| Secondary | 30 Day Readmission Rate | Assessed from discharge date of index hospitalization to 30 days post discharge date | Proportion of patients with readmission within 30 days of index hospitalization discharge |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Proportion of Patients With Progression to a Higher Stage of AKI OR Dialysis OR Death | Within 14 days from randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | 14-day Mortality | Assessed from point of randomization to date of death within 14 days of randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Inpatient Mortality | Assessed from point of randomization to date of death from any cause, up to one year post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | 14-day Dialysis | Assessed from point of randomization to date of first documented dialysis order, within 14 days of randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Inpatient Dialysis | Assess from point of randomization to date of first documented dialysis order during index hospitalization, up to one year post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Discharge on Dialysis | Assessed at point of discharge from index hospitalization, up to one year post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Progression to Stage 2 AKI | Assessed from the date of randomization to 14 days post randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Progression to Stage 3 AKI | Assessed from the date of randomization to 14 days post randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Duration of AKI | Assessed from the date of randomization to the cessation of AKI during index hospitalization, up to one year | Hours | MEDIAN | |
| SECONDARY | 30 Day Readmission Rate | Assessed from discharge date of index hospitalization to 30 days post discharge date | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 outcomesResults by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients With Progression to a Higher Stage of AKI OR Dialysis OR Death | Recommended | 190 | Participants | ||
| Proportion of Patients With Progression to a Higher Stage of AKI OR Dialysis OR Death | Anti-recommended | 193 | Participants | ||
| 14-day Mortality | Recommended | 72 | Participants | ||
| 14-day Mortality | Anti-recommended | 58 | Participants | ||
| Inpatient Mortality | Recommended | 169 | Participants | ||
| Inpatient Mortality | Anti-recommended | 185 | Participants | ||
| 14-day Dialysis | Recommended | 38 | Participants | ||
| 14-day Dialysis | Anti-recommended | 37 | Participants | ||
| Inpatient Dialysis | Recommended | 39 | Participants | ||
| Inpatient Dialysis | Anti-recommended | 41 | Participants |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Recommended | 1,002 | |
| Overall Study | STARTED | Anti-recommended | 1,044 | |
| Overall Study | COMPLETED | Recommended | 1,002 | |
| Overall Study | COMPLETED | Anti-recommended | 1,044 | |
| Overall Study | NOT COMPLETED | Recommended | 0 | |
| Overall Study | NOT COMPLETED | Anti-recommended | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Recommended | 169 | 1,002 |
| Total, all-cause mortality | Anti-recommended | 185 | 1,044 |
| Total, other adverse events | Recommended | 0 | 1,002 |
| Total, other adverse events | Anti-recommended | 0 | 1,044 |
| Total, serious adverse events | Recommended | 0 | 1,002 |
| Total, serious adverse events | Anti-recommended | 0 | 1,044 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DK113191 | Optimizing Electronic Alerts for Acute Kidney Injury | WILSON, FRANCIS PERRY | YALE UNIVERSITY | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2018 to 2022 |
Source NIH RePORTER
Trial comparisons12
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Recommended vs Anti-recommended: Inpatient Dialysis | Trial comparisons |
| Recommended vs Anti-recommended: Proportion of Patients With Progression to a Higher Stage of AKI OR Dialysis OR Death | Trial comparisons |
| Recommended vs Anti-recommended: Inpatient Mortality | Trial comparisons |
| Recommended vs Anti-recommended: Progression to Stage 3 AKI | Trial comparisons |
| Recommended vs Anti-recommended: Progression to Stage 2 AKI | Trial comparisons |
| Recommended vs Anti-recommended: Discharge on Dialysis | Trial comparisons |
| Recommended vs Anti-recommended: 14-day Dialysis | Trial comparisons |
| Recommended vs Anti-recommended: 14-day Mortality | Trial comparisons |
| Recommended vs Anti-recommended: 30 Day Readmission Rate | Trial comparisons |
| Recommended vs Anti-recommended: deaths from any cause | Trial comparisons |
1 to 10 of 12
See all 12 trial comparisonsTests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02786277
GET https://conductscience.org/api/trials/v1/NCT02786277/results?page=2